Osimertinib for EGFR-Positive NSCLC: The Phase III FLAURA Trial


Get Permission

RECENTLY ANNOUNCED DATA from the phase III FLAURA trial showed a statistically significant and clinically meaningful progression-free survival benefit with osimertinib (Tagrisso) compared to current first-line standard-of-care treatment (erlotinib [Tarceva] or gefitinib [Iressa]) in previously untreated patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation–positive non–small cell lung cancer (NSCLC), according to Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca. 

The data suggest the efficacy, safety and tolerability profiles for osimertinib, erlotinib, and gefitinib were consistent with current knowledge. A full evaluation of the FLAURA data is ongoing. Further results will be presented at a forthcoming medical meeting. ■



Advertisement

Advertisement



Advertisement